Download PDF
CC BY 4.0 · World J Nucl Med 2023; 22(02): 100-107
DOI: 10.1055/s-0042-1750406
Original Article

Lesion Analysis in PERCIST 1.0: Clinical Ease versus Research Requisite—Where Does the Balance Exist?

Amit Bhoil
1   Department of Nuclear Medicine, Mahajan Imaging and Labs, New Delhi, India
› Author Affiliations
› Further Information
   Permissions and Reprints

Abstract

Background Semiqualitative parameter SUVmax has been the most frequently used semiquantitative positron emission tomography (PET) parameter for response evaluation, but only metabolic activity of a single (most metabolic) lesion is predicted. Newer response parameters such as tumor lesion glycolysis (TLG) incorporating lesions' metabolic volume or whole-body metabolic tumor burden (MTBwb) are being explored for response evaluation. Evaluation and comparison of response with different semiquantitative PET parameters such as SUVmax and TLG in most metabolic lesion, multiple lesions (max of five), and MTBwb in advanced non-small cell lung cancer (NSCLC) patients were made. The different PET parameters were analyzed for response evaluation, overall survival (OS), and progression-free survival (PFS).

Methods 18F-FDG-PET/CT (18-fluorine-fluorodeoxyglucose positron emission tomography/computed tomography) imaging was performed in 23 patients (M = 14, F = 9, mean age = 57.6 years) with stage IIIB–IV advanced NSCLC before initiation of therapy with oral estimated glomerular filtration rate-tyrosine kinase inhibitor for early and late response evaluation. The quantitative PET parameters such as SUVmax and TLG were measured in single (most metabolic) lesion, multiple lesions, and MTBwb. The parameters SUVmax, TLG, and MTBwb were compared for early and late response evaluation and analyzed for OS and PFS

Results No significant difference in change in response evaluation was seen in patients evaluated with most metabolic lesion, multiple lesions, or MTBwb. Difference in early (DC 22, NDC 1) and late (DC 20, NDC 3) response evaluation was seen that remained unchanged when lesions were measured in terms of number of lesions or the MTBwb. The early imaging was seen to be statistically significant to the OS compared with late imaging.

Conclusions Single (most metabolic) lesion shows similar disease response and OS to multiple lesions and MTBwb. Response evaluation by late imaging offered no significant advantage compared with early imaging. Thus, early response evaluation with SUVmax parameter offers a good balance between clinical ease and research requisition.

Keywords

NSCLC - PERCIST 1.0 - SUV - TLG - MTB - tumor burden - radiomics - lesion analysis

Note

The manuscript has been read and approved by the author that the requirements for authorship as stated earlier in this document have been met, and that author believes that the manuscript represents an honest work, if that information is not provided in another form.




Publication History

Article published online:
28 April 2023

© 2023. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (https://creativecommons.org/licenses/by/4.0/)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 Esposito L, Conti D, Ailavajhala R, Khalil N, Giordano A. Lung cancer: are we up to the challenge?. Curr Genomics 2010; 11 (07) 513-518
    CrossrefPubMedGoogle Scholar
  • 2 Wahl RL, Jacene H, Kasamon Y, Lodge MA. From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors. J Nucl Med 2009; 50 (Suppl. 01) 122S-150S
    CrossrefPubMedGoogle Scholar
  • 3 Mac Manus MP, Hicks RJ, Matthews JP, Wirth A, Rischin D, Ball DL. Metabolic (FDG-PET) response after radical radiotherapy/chemoradiotherapy for non-small cell lung cancer correlates with patterns of failure. Lung Cancer 2005; 49 (01) 95-108
    CrossrefPubMedGoogle Scholar
  • 4 Cachin F, Prince HM, Hogg A, Ware RE, Hicks RJ. Powerful prognostic stratification by [18F]fluorodeoxyglucose positron emission tomography in patients with metastatic breast cancer treated with high-dose chemotherapy. J Clin Oncol 2006; 24 (19) 3026-3031
    CrossrefPubMedGoogle Scholar
  • 5 Boellaard R, Krak NC, Hoekstra OS, Lammertsma AA. Effects of noise, image resolution, and ROI definition on the accuracy of standard uptake values: a simulation study. J Nucl Med 2004; 45 (09) 1519-1527
    PubMedGoogle Scholar
  • 6 Larson SM, Erdi Y, Akhurst T. et al. Tumor treatment response based on visual and quantitative changes in global tumor glycolysis using PET-FDG imaging: the visual response score and the change in total lesion glycolysis. Clin Positron Imaging 1999; 2 (03) 159-171
    CrossrefPubMedGoogle Scholar
  • 7 Nakamoto Y, Zasadny KR, Minn H, Wahl RL. Reproducibility of common semi-quantitative parameters for evaluating lung cancer glucose metabolism with positron emission tomography using 2-deoxy-2-[18F]fluoro-D-glucose. Mol Imaging Biol 2002; 4 (02) 171-178
    CrossrefPubMedGoogle Scholar
  • 8 Guillem JG, Moore HG, Akhurst T. et al. Sequential preoperative fluorodeoxyglucose-positron emission tomography assessment of response to preoperative chemoradiation: a means for determining longterm outcomes of rectal cancer. J Am Coll Surg 2004; 199 (01) 1-7
    CrossrefPubMedGoogle Scholar
  • 9 Punnen S, Haider MA, Lockwood G, Moulding F, O'Malley ME, Jewett MA. Variability in size measurement of renal masses smaller than 4 cm on computerized tomography. J Urol 2006;176(6, Pt 1):2386–2390, discussion 2390
    Google Scholar
  • 10 Bogaerts J, Ford R, Sargent D. et al; RECIST Working Party. Individual patient data analysis to assess modifications to the RECIST criteria. Eur J Cancer 2009; 45 (02) 248-260
    CrossrefPubMedGoogle Scholar
  • 11 Francis RJ, Byrne MJ, van der Schaaf AA. et al. Early prediction of response to chemotherapy and survival in malignant pleural mesothelioma using a novel semiautomated 3-dimensional volume-based analysis of serial 18F-FDG PET scans. J Nucl Med 2007; 48 (09) 1449-1458
    CrossrefPubMedGoogle Scholar
  • 12 Zhang H, Wroblewski K, Jiang Y. et al. A new PET/CT volumetric prognostic index for non-small cell lung cancer. Lung Cancer 2015; 89 (01) 43-49
    CrossrefPubMedGoogle Scholar
  • 13 Zhang H, Wroblewski K, Liao S. et al. Prognostic value of metabolic tumor burden from (18)F-FDG PET in surgical patients with non-small-cell lung cancer. Acad Radiol 2013; 20 (01) 32-40
    CrossrefPubMedGoogle Scholar
  • 14 Liao S, Penney BC, Wroblewski K. et al. Prognostic value of metabolic tumor burden on 18F-FDG PET in nonsurgical patients with non-small cell lung cancer. Eur J Nucl Med Mol Imaging 2012; 39 (01) 27-38
    CrossrefPubMedGoogle Scholar
  • 15 Chen HH, Chiu NT, Su WC, Guo HR, Lee BF. Prognostic value of whole-body total lesion glycolysis at pretreatment FDG PET/CT in non-small cell lung cancer. Radiology 2012; 264 (02) 559-566
    CrossrefPubMedGoogle Scholar
  • 16 Gefitinib (Iressa), prescribing information. April 21, 2022 at: http://www.accessdata.fda.gov/drugsatfda_docs/label/2005/021399s008lbl.pdf
  • 17 Erlotinib (Tarceva), prescribing Information. April 21, 2022 at: http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021743s14s16lbl.pdf
  • 18 Singh N, Aggarwal AN, Behera D, Jindal SK. Intercycle delays during chemotherapy of non-small cell lung cancer in a health care resource-constrained setting and their effect on overall survival. J Thorac Oncol 2010; 5 (02) 236-239
    CrossrefPubMedGoogle Scholar
  • 19 Ratain MJ, Eckhardt SG. Phase II studies of modern drugs directed against new targets: if you are fazed, too, then resist RECIST. J Clin Oncol 2004; 22 (22) 4442-4445
    CrossrefPubMedGoogle Scholar
  • 20 Benjamin RS, Choi H, Macapinlac HA. et al. We should desist using RECIST, at least in GIST. J Clin Oncol 2007; 25 (13) 1760-1764
    CrossrefPubMedGoogle Scholar
  • 21 Takahashi R, Hirata H, Tachibana I. et al. Early [18F]fluorodeoxyglucose positron emission tomography at two days of gefitinib treatment predicts clinical outcome in patients with adenocarcinoma of the lung. Clin Cancer Res 2012; 18 (01) 220-228
    CrossrefPubMedGoogle Scholar
  • 22 Benz MR, Herrmann K, Walter F. et al. (18)F-FDG PET/CT for monitoring treatment responses to the epidermal growth factor receptor inhibitor erlotinib. J Nucl Med 2011; 52 (11) 1684-1689
    CrossrefPubMedGoogle Scholar
  • 23 Kahraman D, Holstein A, Scheffler M. et al. Tumor lesion glycolysis and tumor lesion proliferation for response prediction and prognostic differentiation in patients with advanced non-small cell lung cancer treated with erlotinib. Clin Nucl Med 2012; 37 (11) 1058-1064
    CrossrefPubMedGoogle Scholar
  • 24 Avril N, Sassen S, Schmalfeldt B. et al. Prediction of response to neoadjuvant chemotherapy by sequential F-18-fluorodeoxyglucose positron emission tomography in patients with advanced-stage ovarian cancer. J Clin Oncol 2005; 23 (30) 7445-7453
    CrossrefPubMedGoogle Scholar
  • 25 Sharma P, Gupta A, Patel C, Bakhshi S, Malhotra A, Kumar R. Pediatric lymphoma: metabolic tumor burden as a quantitative index for treatment response evaluation. Ann Nucl Med 2012; 26 (01) 58-66
    CrossrefPubMedGoogle Scholar
  • 26 Berkowitz A, Basu S, Srinivas S, Sankaran S, Schuster S, Alavi A. Determination of whole-body metabolic burden as a quantitative measure of disease activity in lymphoma: a novel approach with fluorodeoxyglucose-PET. Nucl Med Commun 2008; 29 (06) 521-526
    CrossrefPubMedGoogle Scholar
  • 27 Sugawara Y, Zasadny KR, Grossman HB, Francis IR, Clarke MF, Wahl RL. Germ cell tumor: differentiation of viable tumor, mature teratoma, and necrotic tissue with FDG PET and kinetic modeling. Radiology 1999; 211 (01) 249-256
    CrossrefPubMedGoogle Scholar
  • 28 Lee P, Weerasuriya DK, Lavori PW. et al. Metabolic tumor burden predicts for disease progression and death in lung cancer. Int J Radiat Oncol Biol Phys 2007; 69 (02) 328-333
    CrossrefPubMedGoogle Scholar
  • 29 La TH, Filion EJ, Turnbull BB. et al. Metabolic tumor volume predicts for recurrence and death in head-and-neck cancer. Int J Radiat Oncol Biol Phys 2009; 74 (05) 1335-1341
    CrossrefPubMedGoogle Scholar
  • 30 Hussien AE, Furth C, Schönberger S. et al. FDG-PET response prediction in pediatric Hodgkin's lymphoma: impact of metabolically defined tumor volumes and individualized SUV measurements on the positive predictive value. Cancers (Basel) 2015; 7 (01) 287-304
    CrossrefPubMedGoogle Scholar
  • 31 Mileshkin L, Hicks RJ, Hughes BG. et al. Changes in 18F-fluorodeoxyglucose and 18F-fluorodeoxythymidine positron emission tomography imaging in patients with non-small cell lung cancer treated with erlotinib. Clin Cancer Res 2011; 17 (10) 3304-3315
    CrossrefPubMedGoogle Scholar
  • 32 Zander T, Scheffler M, Nogova L. et al. Early prediction of nonprogression in advanced non-small-cell lung cancer treated with erlotinib by using [(18)F]fluorodeoxyglucose and [(18)F]fluorothymidine positron emission tomography. J Clin Oncol 2011; 29 (13) 1701-1708
    CrossrefPubMedGoogle Scholar
  • 33 van Gool MH, Aukema TS, Hartemink KJ, Valdés Olmos RA, van Tinteren H, Klomp HM. FDG-PET/CT response evaluation during EGFR-TKI treatment in patients with NSCLC. World J Radiol 2014; 6 (07) 392-398
    CrossrefPubMedGoogle Scholar
  • 34 Lemarignier C, Martineau A, Teixeira L. et al. Correlation between tumour characteristics, SUV measurements, metabolic tumour volume, TLG and textural features assessed with 18F-FDG PET in a large cohort of oestrogen receptor-positive breast cancer patients. Eur J Nucl Med Mol Imaging 2017; 44 (07) 1145-1154
    CrossrefPubMedGoogle Scholar